REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
Board Change Serabi Gold plc (“Serabi” or the “Company”) (AIM: SRB, TSX: SBI, OTCQX :…
To give an overview of the 2025 Q1 financial results, LHV Group organised an investor…
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX,…
Newest AI enhancement to the Content Authoring Tool (CAT) affirms Litmos’ mission to create better…
Delray Beach, FL, April 22, 2025 (GLOBE NEWSWIRE) -- The Graphene Market is projected to grow…
Company announcement no. 19 2025Danske BankBernstorffsgade 40DK-1577 København VTel. + 45 33 44 00…
This website uses cookies.